Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 14,184 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 14,184 shares of the stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $51.62, for a total transaction of $732,178.08. Following the completion of the transaction, the chief executive officer owned 50,760 shares of the company’s stock, valued at $2,620,231.20. This trade represents a 21.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total transaction of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total value of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total value of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.47, for a total value of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total value of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.55, for a total value of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total transaction of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total transaction of $117,338.64.

Phibro Animal Health Price Performance

Shares of PAHC traded down $0.22 during mid-day trading on Wednesday, hitting $51.52. The company’s stock had a trading volume of 352,907 shares, compared to its average volume of 265,479. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The firm has a 50-day moving average price of $40.54 and a 200 day moving average price of $38.75. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $56.30. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 0.80 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, research analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 21.33%.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently bought and sold shares of the business. Penserra Capital Management LLC acquired a new position in shares of Phibro Animal Health in the 3rd quarter valued at about $519,000. Capricorn Fund Managers Ltd purchased a new position in Phibro Animal Health during the third quarter valued at approximately $10,233,000. Allspring Global Investments Holdings LLC purchased a new position in Phibro Animal Health during the third quarter valued at approximately $8,931,000. Bailard Inc. acquired a new position in Phibro Animal Health in the 2nd quarter valued at approximately $259,000. Finally, Squarepoint Ops LLC purchased a new stake in Phibro Animal Health in the 2nd quarter worth approximately $813,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PAHC. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday. JPMorgan Chase & Co. boosted their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Phibro Animal Health has a consensus rating of “Hold” and an average price target of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.